

FORM 51-102F3

MATERIAL CHANGE REPORT

Item 1. Name and Address of Company

PanGenomic Health Inc. (the "Company")

315-1275 West 6th Avenue

Vancouver, BC V6H 1A6

Item 2. Date of Material Change

November 7, 2024 and November 14, 2024.

Item 3. News Release

The news releases (the "News Releases") were issued on November 7, 2024 and November 14, 2024 and disseminated by TheNewswire.

Item 4. Summary of Material Change

On November 7, 2024, the Company announced a consolidation (the "Consolidation") of all of its issued and outstanding Class A Common Shares ("Common Shares") on the basis of five (5) pre-Consolidation Common Shares for every one (1) post-Consolidation Common Share

On November 14, 2024, the Company completed the Consolidation. The Common Shares began trading on a consolidated basis on the Canadian Securities Exchange on November 14, 2024.

Item 5. Full Description of Material Change

See the News Releases announcing the Consolidation and the completion of the Consolidation, attached hereto as Schedule "A".

Item 6. Reliance on Subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7. Omitted Information

None.

Item 8. Executive Officer

Tammy Gillis

Chief Financial Officer, Treasurer and Secretary

(778) 743-4642

Item 9. Date of Report

November 14, 2024.

SCHEDULE "A"

NEWS RELEASES

(See attached)

PanGenomic Health Announces Proposed Consolidation

Vancouver, British Columbia, November 7, 2024 – PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) announces that it intends to consolidate all of its issued and outstanding Class A Common Shares (the "Common Shares") on the basis of five (5) pre-Consolidation Common Shares for every one (1) post-Consolidation Common Share (the "Consolidation").

There are currently 31,999,068 Common Shares issued and outstanding prior to completion of the Consolidation. Upon completion of the Consolidation, there are expected to be approximately 6,399,814 Common Shares issued and outstanding, subject to adjustment for fractional Common Shares. No fractional Common Shares will be issued as a result of the Consolidation. Fractional Common Shares equal to or greater than one-half (1/2) will be rounded up to the nearest whole number. Fractional Common Shares of less than one-half (1/2) will be cancelled without any repayment of capital or other compensation.

In accordance with Policy 4 of the CSE, shareholders of the Company holding more than 50% of the outstanding Common Shares as at November 4, 2024 approved the Consolidation by written consent.

The Consolidation is expected to be effected, and the Common Shares are expected to begin trading on a post-consolidation basis, on November 14, 2024. Completion of the Consolidation is subject to approval by the CSE.

The new CUSIP number for the post-Consolidation Common Shares will be 69842E403 and the new ISIN will be CA69842E4031. The Common Shares will continue to trade on the CSE under the symbol "NARA," and the Company's name will not change.

Management of the Company believes that the Consolidation will provide the Company with a share structure that will better attract future capital financing and enhance growth opportunities.

About PanGenomic Health

PanGenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. The Company's initial focus is to support mental health. Registered as a British Columbia benefit company, PanGenomic Health's mission is to promote and improve the health and wellness of people and society by providing a technology platform that identifies plant-based solutions tailored to the health profile of each individual.

For more information, please contact:

Jerry Lai, Investor Relations
PanGenomic Health Inc.
+1 778 743 4642
ir@pangenomic.com

This news release includes certain statements that may be deemed "forward-looking statements", including statements respecting the services to be provided by PanGenomic Health and the consideration to be paid to PanGenomic Health. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "would", "project", "should", "believe" and similar

expressions are intended to identify forward-looking statements. Although PanGenomic Health believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because PanGenomic Health can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in PanGenomic Health's disclosure documents which can be found under PanGenomic Health's profile on www.sedarplus.ca.

The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.

PanGenomic Health Announces Completion of Consolidation

Vancouver, British Columbia, November 14, 2024 – PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) announces the completion of the consolidation (the "Consolidation") of all of its issued and outstanding Class A Common Shares ("Common Shares") on the basis of five (5) pre-Consolidation Common Shares for every one (1) post-Consolidation Common Share was completed, effective November 14, 2024.

Immediately upon completion of the Consolidation, there were 6,399,812 Common Shares issued and outstanding. No fractional Common Shares were issued as a result of the Consolidation. Fractional Common Shares equal to or greater than one-half (1/2) were rounded up to the nearest whole number. Fractional Common Shares equal to less than one-half (1/2) were cancelled without any repayment of capital or other compensation.

The Common Shares began trading on a consolidated basis on the Canadian Securities Exchange (the "CSE") on November 14, 2024.

The new CUSIP number for the post-Consolidation Common Shares is 69842E403 and the new ISIN is CA69842E4031. The Common Shares continue to trade on the CSE under the symbol "NARA", and the Company's name did not change.

Management of the Company believes that the Consolidation will provide the Company with a share structure that will better attract future capital financing and enhance growth opportunities.

About PanGenomic Health

PanGenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. The Company's initial focus is to support mental health. Registered as a British Columbia benefit company, PanGenomic Health's mission is to promote and improve the health and wellness of people and society by providing a technology platform that identifies plant-based solutions tailored to the health profile of each individual.

For more information, please contact:

Jerry Lai, Investor Relations
PanGenomic Health Inc.
+1 778 743 4642
ir@pangenomic.com

This news release includes certain statements that may be deemed "forward-looking statements", including statements respecting the services to be provided by PanGenomic Health and the consideration to be paid to PanGenomic Health. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "would", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although PanGenomic Health believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because PanGenomic Health can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of

factors and risks including various risk factors discussed in PanGenomic Health's disclosure documents which can be found under PanGenomic Health's profile on www.sedarplus.ca.

The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.